Aurobindo Pharma Limited has successfully concluded its share buyback programme, repurchasing 54,23,728 fully paid-up equity shares of face value ₹1/- each at a price of ₹1,475 per share, for an aggregate amount not exceeding ₹800,00,00,000 (Rupees Eight Hundred Crore only). The buyback was conducted through the tender offer route in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018. The Post Buyback Public Advertisement, dated May 7, 2026, was published on May 8, 2026 in Financial Express (English, all editions), Jansatta (Hindi, all editions), and Nava Telangana (Telugu, Hyderabad edition).

Buyback Overview

The buyback was announced with a record date of April 17, 2026, and the tendering period ran from April 23, 2026 to April 29, 2026. The buyback size constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements as at March 31, 2025, respectively. The Board resolution authorising the buyback was passed on April 6, 2026.

The following table summarises the key parameters of the buyback:

Bid Response and Settlement

The buyback witnessed robust participation from shareholders. KFin Technologies Limited, the Registrar to the Buyback, considered a total of 26,568 valid bids for 2,94,73,022 equity shares, which is approximately 5.43 times the maximum number of equity shares proposed to be bought back. The category-wise breakdown of valid bids is as follows:

Settlement of all valid bids was completed by Indian Clearing Corporation Limited on May 7, 2026. Direct funds pay-out was made to eligible shareholders whose equity shares were accepted under the buyback. All equity shares tendered were in dematerialised form; no equity shares were tendered in physical form. Unaccepted dematerialised equity shares were returned to respective eligible shareholders or custodians by release of lien by the Clearing Corporation on May 7, 2026. Communication of acceptance or rejection was dispatched by the Registrar via email on May 7, 2026.

Capital Structure: Pre and Post Buyback

The buyback has resulted in a reduction in the company's issued, subscribed, and fully paid-up share capital. The capital structure before and after the buyback is detailed below:

* Subject to extinguishment of 54,23,728 equity shares accepted in the Buyback.

The extinguishment of the 54,23,728 equity shares accepted under the buyback, all of which are in dematerialised form, is currently under process and is expected to be completed on or before May 18, 2026.

Shareholding Pattern: Pre and Post Buyback

The shareholding pattern of the Company, as of the Record Date (April 17, 2026) and post completion of the Buyback, is as follows:

* Subject to extinguishment of 54,23,728 equity shares accepted in the Buyback.

Major Shareholders Participating in the Buyback

The following eligible shareholders tendered equity shares exceeding 1% of the total equity shares bought back under the buyback:

* Subject to extinguishment of 54,23,728 equity shares accepted in the Buyback.

Directors' Responsibility

As per Regulation 24(i)(a) of the Buyback Regulations, the Board of Directors of Aurobindo Pharma accepts full responsibility for the information contained in the Post Buyback Public Advertisement and confirms that it contains true, factual, and material information without any misleading content. The Post Buyback Public Advertisement was issued under the authority of the Board of Directors in terms of the resolution passed on April 6, 2026, and was signed by Managing Director K. Nithyananda Reddy, Whole-time Director M. Madan Mohan Reddy, and Company Secretary & Compliance Officer B. Adi Reddy, dated May 7, 2026, at Hyderabad.

Aurobindo Pharma Limited disclosed, pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, that its Unit-VII manufacturing facility has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (US FDA). The company communicated this development to both the National Stock Exchange of India Limited and BSE Limited through a formal regulatory filing signed by Company Secretary B. Adi Reddy.

US FDA Inspection Overview

The US FDA conducted an inspection of Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana. The key details of the inspection are summarised below:

VAI Classification and Inspection Closure

Following the inspection, the US FDA issued a Form 483 with a total of 9 observations. Subsequently, the unit received the Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI). The FDA has formally concluded that the inspection is now closed. This disclosure was made in reference to the company's earlier communication dated February 10, 2026, which had informed the exchanges of the inspection and the issuance of Form 483.

Regulatory Disclosure

The filing was made in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The disclosure was digitally signed by B. Adi Reddy, Company Secretary of Aurobindo Pharma Limited, on May 6, 2026. The company is headquartered at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.